New technologies are enabling the arrival of the much-awaited "$1000 genome" the ability to sequence an individual's or a tumor's entire genome quickly and relatively inexpensively [whole genome sequencing (WGS)]. WGS is now being offered in clinical care and is expected to become more widely used in the near future. However, this technological advance threatens to outpace our ability to use it effectively in clinical practice and to address the associated health policy issues. Kathryn Phillips, Professor of Health Economics and Health Services Research and Founder/PI of the UCSF Center for Translational and Policy Research on Personalized Medicine (TRANSPERS) will discuss work on evaluating the potential benefit-risk tradeoffs of WGS from the perspectives of patients, providers, the health care delivery system, and society by using systematic and quantitative approaches.
We are addressing questions such as:
-- What information do patients and providers want to know and how do they want to learn information about their genome?
-- How can health payers, guideline organizations, and society facilitate the appropriate use of WGS while at the same time not opening "Pandora's box"?
ctm2101 [at] columbia [dot] edu